ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
US stocks: S&P 500 ends nearly flat as US-Iran talks help stocks pare losses
S&P 500 ended almost flat as Microsoft declined, while Meta Platforms recorded gains amid ongoing market fluctuations. Oil prices surged following geopolitical tensions and a